Resources

Real-world data (RWD) and the real-world evidence (RWE) derived from analysis of the data are a cornerstone of clinical advancements in today’s fast-paced research environment

The bispecific antibodies (bsAbs) teclistamab and talquetamab have received United States Food and Drug Administration (FDA) approval for use in relapsed/refractory multiple myeloma (MM) following remarkable single-agent activity in early-phase clinical trials.

The healthcare and clinical research industries are undergoing a seismic shift. Rapid advancements in real-world data (RWD), artificial intelligence (AI), and patient-centric approaches are rewriting the playbook for clinical trials and treatment development. The future of healthcare is here, and organizations that embrace these changes will be at the forefront of innovation. 

Clinical trial site identification (ID) and outreach are often inefficient due to manual, paper-based processes, placing a heavy burden on both contract research organizations (CROs) and the clinical study sites with which they work.

Clinical trials are vital to drug development but often face challenges such as slow patient recruitment, high costs, and suboptimal trial designs. Today, artificial intelligence (AI) and real-world data (RWD) are transforming this process by optimizing trial protocols, enhancing recruitment, and accelerating timelines.  

The healthcare industry is on the cusp of transformation. Artificial intelligence (AI)-driven insights, real-world evidence (RWE)-backed regulatory decisions, and a new era of patient-centricity are already shaping the next chapter of healthcare.

Clinical trials are the backbone of medical advancements, yet they often face significant hurdles in their final stages.

In the evolving landscape of clinical research, the era of one-size-fits-all clinical trials is firmly behind us. Regulatory bodies and industry leaders alike recognize the necessity of diverse representation in trials to ensure that medical treatments are effective for all populations.

Multiple myeloma (MM) is a rare and complex blood cancer that affects plasma cells in the bone marrow. These malignant cells accumulate and interfere with normal blood cell production, leading to complications such as anemia, kidney dysfunction, bone lesions, and increased susceptibility to infections.

The integration of digital technology is transforming clinical research, improving the efficiency of trial design and execution. A key innovation in this space is the digital waiting room, which leverages real-world data (RWD) and artificial intelligence (AI) to enhance the critical “last mile” of a trial—when sites are activated, and patient recruitment begins. 

SCOPE 2025, held from February 3-6 in Orlando, Florida, brought together over 4,500 leaders in clinical operations and research to discuss the latest advancements in clinical trial innovation, planning, management, and operations

Partnership taps real-world data to accelerate clinical trials, research, and drug development in Japan.